SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001169245-21-000100
Filing Date
2021-11-03
Accepted
2021-11-03 08:04:44
Documents
14
Period of Report
2021-11-03
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K phas-20211103.htm   iXBRL 8-K 35908
2 EX-99.1 bentracimabphase2btopliner.htm EX-99.1 18034
6 image_0.jpg GRAPHIC 198989
  Complete submission text file 0001169245-21-000100.txt   478403

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT phas-20211103.xsd EX-101.SCH 1914
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT phas-20211103_lab.xml EX-101.LAB 25998
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT phas-20211103_pre.xml EX-101.PRE 13731
7 EXTRACTED XBRL INSTANCE DOCUMENT phas-20211103_htm.xml XML 11441
Mailing Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355
Business Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355 (610) 981-6500
PhaseBio Pharmaceuticals Inc (Filer) CIK: 0001169245 (see all company filings)

IRS No.: 030375697 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38697 | Film No.: 211373779
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences